|
1
|
Bosetti C, Turati F and La Vecchia C:
Hepatocellular carcinoma epidemiology. Best Practice & Res Clin
Gastroenterol. 28:753–770. 2014. View Article : Google Scholar
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fares N and Peron JM: Epidemiology,
natural history and risk factors of hepatocellular carcinoma. Rev
Prat. 63:216–217. 2013.(In French). PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alakurtti S, Makela T, Koskimies S and
Yli-Kauhaluoma J: Pharmacological properties of the ubiquitous
natural product betulin. European journal of pharmaceutical
sciences: official journal of the European Federation for
Pharmaceutical Sciences. 29:1–13. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tolstikov GA, Flekhter OB, Shultz EE,
Baltina LA and Tolstikov AG: Betulin and its derivatives. Chemistry
and biological activity. Chemistry for Sustainable Development.
13:1–29. 2005.
|
|
7
|
Huyke C, Reuter J, Rodig M, Kersten A,
Laszczyk M, Scheffler A, Nashan D and Schempp C: Treatment of
actinic keratoses with a novel betulin-based oleogel. A
prospective, randomized, comparative pilot study. J Dtsch Dermatol
Ges. 7:128–133. 2009.(In English, German). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soica C, Dehelean C, Danciu C, Wang HM,
Wenz G, Ambrus R, Bojin F and Anghel M: Betulin complex in
gamma-cyclodextrin derivatives: properties and antineoplasic
activities in in vitro and in vivo tumor models. Int J Mol Sci.
13:14992–15011. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rzeski W, Stepulak A, Szymanski M,
Juszczak M, Grabarska A, Sifringer M, Kaczor J and
Kandefer-Szerszen M: Betulin elicits anti-cancer effects in tumour
primary cultures and cell lines in vitro. Basic Clin Pharmacol
Toxicol. 105:425–432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hwang BY, Chai HB, Kardono LB, Riswan S,
Farnsworth NR, Cordell GA, Pezzuto JM and Kinghorn AD: Cytotoxic
triterpenes from the twigs of Celtis philippinensis.
Phytochemistry. 62:197–201. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu RJ, Hsu YC, Chen SP, Fu CL, Yu JC,
Chang FW, Chen YH, Liu JM, Ho JY and Yu CP: The triterpenoids of
Hibiscus syriacus induce apoptosis and inhibit cell migration in
breast cancer cells. BMC Complement Altern Med. 15:652015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, He K, Huang Y, Zheng D, Gao C, Cui L
and Jin YH: Betulin induces mitochondrial cytochrome c release
associated apoptosis in human cancer cells. Mol carcinogene.
49:630–640. 2010.
|
|
13
|
Li XD, Zhang YJ and Han JC: Betulin
inhibits lung carcinoma proliferation through activation of AMPK
signaling. Tumour biol. 35:11153–11158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gauthier C, Legault J, Lavoie S, Rondeau
S, Tremblay S and Pichette A: Synthesis and cytotoxicity of
bidesmosidic betulin and betulinic acid saponins. J natural prod.
72:72–81. 2009. View Article : Google Scholar
|
|
15
|
Yim NH, Jung YP, Kim A, Kim T and Ma JY:
Induction of apoptotic cell death by betulin in multidrug-resistant
human renal carcinoma cells. Oncol Rep. 34:1058–1064. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dehelean CA, Soica C, Ledeti I, Aluas M,
Zupko IG, Luscan A, Cinta-Pinzaru S and Munteanu M: Study of the
betulin enriched birch bark extracts effects on human carcinoma
cells and ear inflammation. Chem Central J. 6:1372012. View Article : Google Scholar
|
|
17
|
Saudagar P and Dubey VK: Molecular
mechanisms of in vitro betulin-induced apoptosis of Leishmania
donovani. TAm J Trop Med Hyg. 90:354–360. 2014. View Article : Google Scholar
|
|
18
|
Kommera H, Kaluderovic GN, Dittrich S,
Kalbitz J, Drager B, Mueller T and Paschke R: Carbamate derivatives
of betulinic acid and betulin with selective cytotoxic activity.
Bio Organic Med Chem Letters. 20:3409–3412. 2010. View Article : Google Scholar
|
|
19
|
Drag-Zalesinska M, Kulbacka J, Saczko J,
Wysocka T, Zabel M, Surowiak P and Drag M: Esters of betulin and
betulinic acid with amino acids have improved water solubility and
are selectively cytotoxic toward cancer cells. Bio Organic Med Chem
Letters. 19:4814–4817. 2009. View Article : Google Scholar
|
|
20
|
Santos RC, Salvador JA, Marin S and
Cascante M: Novel semisynthetic derivatives of betulin and
betulinic acid with cytotoxic activity. Bio Organic Med Chem.
17:6241–6250. 2009. View Article : Google Scholar
|
|
21
|
Yang SJ, Liu MC, Xiang HM, Zhao Q, Xue W
and Yang S: Synthesis and in vitro antitumor evaluation of betulin
acid ester derivatives as novel apoptosis inducers. Eur J Med Chem.
102:249–255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Llovet JM and Hernandez-Gea V:
Hepatocellular carcinoma: reasons for phase III failure and novel
perspectives on trial design. Clin Cancer Res. 20:2072–2079. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weber AM and Ryan AJ: ATM and ATR as
therapeutic targets in cancer. Pharmacol Ther. 149:124–138. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee YS, Choi KM, Kim W, Jeon YS, Lee YM,
Hong JT, Yun YP and Yoo HS: Hinokitiol inhibits cell growth through
induction of S-phase arrest and apoptosis in human colon cancer
cells and suppresses tumor growth in a mouse xenograft experiment.
J Nat Prod. 76:2195–2202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shin EM, Kim S, Merfort I and Kim YS:
Glycyrol induces apoptosis in human Jurkat T cell lymphocytes via
the Fas-FasL/caspase-8 pathway. Plantamedica. 77:242–247. 2011.
|
|
27
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tamura D, Arao T, Tanaka K, Kaneda H,
Matsumoto K, Kudo K, Aomatsu K, Fujita Y, Watanabe T, Saijo N, et
al: Bortezomib potentially inhibits cellular growth of vascular
endothelial cells through suppression of G2/M transition. Cancer
Sci. 101:1403–1408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boutros R, Lobjois V and Ducommun B: CDC25
phosphatases in cancer cells: key players? Good targets? Nature
reviews. Cancer. 7:495–507. 2007.PubMed/NCBI
|
|
30
|
Thornberry NA and Lazebnik Y: Caspases:
enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brown JM and Attardi LD: The role of
apoptosis in cancer development and treatment response. Nature
reviews. Cancer. 5:231–237. 2005.PubMed/NCBI
|
|
32
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li P, Nijhawan D, Budihardjo I,
Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and
dATP-dependent formation of Apaf-1/caspase-9 complex initiates an
apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ghavami S, Hashemi M, Ande SR, Yeganeh B,
Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, et
al: Apoptosis and cancer: mutations within caspase genes. J Med
Gene. 46:497–510. 2009. View Article : Google Scholar
|
|
35
|
Sola S, Morgado AL and Rodrigues CM: Death
receptors and mitochondria: Τwo prime triggers of neural apoptosis
and differentiation. Biochim Biophys Acta. 1830:2160–2166. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sasi N, Hwang M, Jaboin J, Csiki I and Lu
B: Regulated cell death pathways: new twists in modulation of BCL2
family function. Mol Cancer Ther. 8:1421–1429. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Salvesen GS and Dixit VM: Caspase
activation: the induced-proximity model. Proc Natl Acad Sci USA.
96:10964–10967. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei MC, Zong WX, Cheng EH, Lindsten T,
Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and
Korsmeyer SJ: Proapoptotic BAX and BAK: Α requisite gateway to
mitochondrial dysfunction and death. Science. 292:727–730. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi Y: Mechanisms of caspase activation
and inhibition during apoptosis. Molecular cell. 9:459–470. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Manning BD and Cantley LC: AKT/PKB
signaling: Νavigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer treatment. Ann Rev Med. 67:11–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Neri LM, Cani A, Martelli AM, Simioni C,
Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey
JA, et al: Targeting the PI3K/Akt/mTOR signaling pathway in
B-precursor acute lymphoblastic leukemia and its therapeutic
potential. Leukemia. 28:739–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
